Study on the mechanism of tacrolimus inhibiting B cell differentiation and development in the treatment of myasthenia gravis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061488

Enrollment

Unknown

Registered

2022-06-27

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myasthenia gravis (MG)

Interventions

experimental group:Tacrolimus capsules, 2-3mg / day, bid

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed MG patients; 2. Aged 18-65 years.

Exclusion criteria

Exclusion criteria: 1. Use glucocorticoid, immunosuppressant or thymotomy within 3 months before enrollment. 2. Hyperthyroidism and other autoimmune diseases, blood-borne diseases, viral hepatitis, tuberculosis and other infectious diseases. 3. Have thymus disease.

Design outcomes

Primary

Measure	Time frame
Quantitative Myasthenia Gravis (QMG) Score;	—

Secondary

Measure	Time frame
Blood concentration of tacrolimus;Myasthenia gravis autoantibodies;Serum anti-ACHr -Ab IgG titer;	—

Countries

China

Contacts

Public ContactQiu Wei

qiuwei@mail.sysu.edu.cn+86 15899968330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026